Skip to main content
Log in

Intra-individual consistency of prednisolone kinetics during long-term prednisone treatment

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Summary

Eleven patients on long-term prednisone treatment were studied on two occasions separated by 45 to 325 days. In 10 patients the total body clearance of prednisolone only changed about 10%. In one case a 78.5% decrease was observed after stopping treatment with rifampicin and isoniazide. No association was found between the prednisone dose rate (mg/kg per month), patient age or mean endogenous plasma hydrocortisone level and prednisolone clearance/kg. The results indicate considerable intra-individual consistency of prednisolone kinetics if other conditions are not changed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Henderson RG, Wheatley T, English J, Chakraborty J, Marks V (1979) Variation in plasma prednisolone concentrations in renal transplant recipients given enteric-coated prednisolone. Br J Med 1: 1534–1536

    Google Scholar 

  2. Gambertoglio JG, Amend WJC Jr, Benet LZ (1980) Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review. J Pharmacokin et Biopharm 8: 1–52

    Google Scholar 

  3. Frey FJ, Lozada F, Guentert T, Frey BM (1981) A single dose of azathioprine does not affect the pharmacokinetics of prednisolone following oral prednisone. Eur J Clin Pharmacol 19: 209–212

    Google Scholar 

  4. Matsuzawa T, Sugimoto N, Ishiguro I (1981) A simple micromethod for determining human serum cortisol by high-pressure liquid chromatography using 0.1 ml serum. Anal Biochem 115: 250–253

    Google Scholar 

  5. Gambertoglio JG, Vincenti F, Feduska NJ, Birnbaum J, Salvatierra O Jr, Amend WJC Jr (1980) Prednisolone disposition in cushingoid and non-cushingoid kidney transplant patients. J Clin Endocrinol Metab 51: 561–565

    Google Scholar 

  6. Frey FJ, Amend WJC, Lozada F, Frey BM, Holford NHG, Benet LZ (1982) Pharmacokinetics of prednisolone and endogenous hydrocortisone levels in cushingoid and non-cushingoid patients. Eur J Clin Pharmacol 21: 235–242

    Google Scholar 

  7. Gambertoglio JG, Felix JF, Holford NHG, Birnham JL, Lizak PS, Vincenti F, Feduska NJ, Salvatierra O Jr, Amend MJC Jr (1982) Prednisone and prednisolone bioavailability in renal transplant patients. Kidney Int 21: 621–626

    Google Scholar 

  8. Rose JQ, Yurchak AM, Jusko WJ (1978) Bioavailability of two 50 mg prednisone formulations in man. (Abstract) APhA Acad Pharm Sci 8: 138

    Google Scholar 

  9. Meikle AW, Weed JA, Tyler FH (1975) Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunoassays. J Clin Endocrinol Metab 41: 717–721

    Google Scholar 

  10. Bergrem H, Grøttum P, Rugstad HE (1983) Pharmacokinetics and protein binding of prednisolone after oral and intravenous administration. Eur J Clin Pharmacol 24: 415–419

    Google Scholar 

  11. Uribe M, Schalm SW, Summerskill WHJ, Go VLW (1978) Oral prednisone for chronic active liver disease: dose responses and bioavailability studies. Gut 19: 1131–1135

    Google Scholar 

  12. Davis M, Williams R, Chakraborty J, English J, Marks V, Ideo G, Tempini S (1978) Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability. Br J Clin Pharmacol 5: 501–505

    Google Scholar 

  13. Frey FJ, Amend WJC Jr, Lozada F, Frey BM, Benete LZ (1981) Endogenous hydrocortisone, a possible factor contributing to the genesis of cushingoid habitus in patients on prednisone. J Clin Endocrinol Metab 53: 1076–1080

    Google Scholar 

  14. Araki Y, Yokota O, Tatsuo K, Kashima M, Miyazaki T (1965) Steroid dynamics. Academic Press, New York, p 463

    Google Scholar 

  15. Kozower M, Veatch L, Kaplan M (1974) Decreased clearance of prednisolone, a factor in the development of corticosteroid side-effects. J Clin Endocrinol Metab 38: 407–412

    Google Scholar 

  16. Öst L, Björkhem I, Bahr C von (1984) Clinical value of assessing prednisolone pharmacokinetics before and after renal transplantation. Eur J Clin Pharmacol 26: 363–369

    Google Scholar 

  17. McAllister WAC, Thompson PJ, Al-Habet SM, Rogers HJ (1983) Rifampicin reduces effectiveness and bioavailability of prednisone. Br Med J 286: 923–925

    Google Scholar 

  18. Wassner SJ, Malekzadeh MH, Pennisi AJ, Ettenger RB, Uittenbogaart CH, Fine RN (1977) Allograft survial in patients receiving anticonvulsant medications. Clin Nephrol 8: 293–297

    Google Scholar 

  19. Buffington GA, Dominguez JH, Piering WF, Hebert LA, Kauffman HM, Lemann J (1976) Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. Am Med Assoc 236: 1958–1960

    Google Scholar 

  20. Bergrem H, Hervell J, Flatmark A (1983) Different prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients. Clin Pharmacol Ther 33: 249

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Langhoff, E., Flachs, H., Ladefoged, J. et al. Intra-individual consistency of prednisolone kinetics during long-term prednisone treatment. Eur J Clin Pharmacol 26, 651–653 (1984). https://doi.org/10.1007/BF00543505

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00543505

Key words

Navigation